Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib in Third-line and Later SCLC
NCT02995187Phase 2Unknown
- Sponsor
- Chinese Academy of Medical Sciences
- Start
- Dec 2016
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib in small cell lung cancer (SCLC), sponsored by Chinese Academy of Medical Sciences. Primary endpoint: Progression-free survival up to 3 years. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT02995187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02995187.